D. Hose

D. Hose, H. Goldschmidt, A. Jauch, 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions.

D. Hose, M. Gelinsky, Martin Müller, 2015, Macromolecular bioscience.

Immunochemical, ultrastructural and electrophysiological investigations of bone-derived stem cells in the course of neuronal differentiation.

D. Hose, V. Alt, R. Schnettler, 2006, Bone.

Human reaming debris: a source of multipotent stem cells.

D. Hose, O. Kilian, V. Alt, 2005, Bone.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

D. Hose, H. Goldschmidt, G. Morgan, 2015, BMC Medical Genomics.

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy

T. Rème, B. Klein, J. Moreaux, 2014, Oncotarget.

Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma

D. Hose, A. Seckinger, G. Cowan, 2015, Oncotarget.

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumor mass and biology

D. Hose, H. Goldschmidt, A. Jauch, 2015 .

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology

D. Hose, H. Goldschmidt, A. Jauch, 2016, European Radiology.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma

B. Klein, D. Hose, C. Bokemeyer, 2014, Leukemia.

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells

J. D. Vos, T. Rème, M. Jourdan, 2005, Oncogene.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

D. Hose, H. Goldschmidt, A. Jauch, 2016, Haematologica.

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

M. Beksac, D. Hose, F. Zhan, 2021, Molecular Cancer.

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

D. Hose, H. Goldschmidt, P. Sonneveld, 2013, Blood.

Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide

D. Hose, H. Goldschmidt, P. Sonneveld, 2012 .

Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model

D. Hose, H. Goldschmidt, S. Ševčíková, 2020, British journal of haematology.

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

C. Klein, D. Hose, F. Prósper, 2017, Cancer cell.

Target Expression , Genera tion , Preclinical Activity , and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM 801 for Multiple Myeloma Treatment Graphical

C. Klein, D. Hose, F. Prósper, 2022 .

CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment

S. Haferkamp, M. Boutros, D. Hose, 2020, Cancer Immunology Research.

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.

T. Rème, J. Rossi, B. Klein, 2013, Blood.

SULFs in human neoplasia: implication as progression and prognosis factors

B. Klein, J. Moreaux, D. Hose, 2011, Journal of Translational Medicine.

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome

D. Hose, H. Goldschmidt, F. Zhan, 2018, Blood Cancer Journal.

Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.

G. Requirand, T. Rème, B. Klein, 2022 .

Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma 1

G. Requirand, B. Klein, D. Hose, 2009 .

Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.

B. Klein, D. Hose, H. Goldschmidt, 2013, Experimental hematology.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

M. Kersten, D. Hose, H. Goldschmidt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timing of the high-dose therapy in the area of new drugs.

D. Hose, H. Goldschmidt, U. Bertsch, 2011, Srpski arhiv za celokupno lekarstvo.

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

G. Requirand, J. Rossi, B. Klein, 2009, British Journal of Cancer.

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Ho, 2016, Oncotarget.

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma

D. Hose, F. Zhan, A. Seckinger, 2020, Leukemia.

Induction of angiogenesis by normal and malignant plasma cells.

T. Rème, J. Rossi, B. Klein, 2009, Blood.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

G. Requirand, T. Rème, B. Klein, 2018, British Journal of Cancer.

Quantification of plasma cell dynamics using mathematical modelling

D. Hose, A. Marciniak-Czochra, A. Seckinger, 2018, Royal Society Open Science.

Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)

D. Hose, H. Goldschmidt, A. Jauch, 2007, Bone Marrow Transplantation.

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2014, Oncotarget.

Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2008 .

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2008 .

Targeting NF‐κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth

J. D. Vos, T. Rème, M. Jourdan, 2007, British journal of haematology.

chemokines promoting myeloma cell migration Osteoclast-gene expression profiling reveals osteoclast-derived CCR2

T. Rème, B. Klein, J. Moreaux, 2011 .

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

G. Requirand, T. Rème, B. Klein, 2011, Blood.

CD200 is a new prognostic factor in multiple myeloma.

T. Rème, J. Rossi, B. Klein, 2006, Blood.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression

J. Zimmermann, V. Beneš, B. Klein, 2015, Oncotarget.

Patient and Caregiver Experience Decision Factors in Treatment Decision Making-Results of a Systematic Literature Review of Multiple Myeloma Decision Aids.

D. Hose, P. Keown, J. Harousseau, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance

D. Hose, A. Jauch, A. Ho, 2018, Front. Immunol..

Human B Cell to Plasma Cell Differentiation Preplasmablast Population in the Process of Characterization of a Transitional

J. D. Vos, K. Tarte, T. Rème, 2011 .

Determined by Microarray Analysis Expression Patterns and Prognosis Value Cancer/Testis Genes in Multiple Myeloma:

J. D. Vos, P. Raynaud, V. Pantesco, 2007 .

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma

G. Requirand, B. Klein, J. Moreaux, 2017, Oncotarget.

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

D. Hose, H. Goldschmidt, F. Bassermann, 2021, Blood advances.

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

J. Moreaux, D. Hose, C. Heirman, 2018, Cancer research.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro

D. Hose, H. Goldschmidt, A. Ho, 2016, Oncoimmunology.

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, Leukemia.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance

D. Hose, H. Goldschmidt, A. Jauch, 2018, Leukemia.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

Axel Benner, John D. Shaughnessy, Thomas Hielscher, 2011, Haematologica.

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach

J. Moreaux, D. Hose, S. Verhulst, 2022, Frontiers in Cell and Developmental Biology.

BMP‐6 Loaded Polyelectrolyte Complex Nanoparticles Inducing Osteogenic Differentiation and Apoptosis of Malignant Plasma Cells for Local Treatment of Multiple Myeloma

D. Hose, E. A. Cavalcanti-Adam, A. Seckinger, 2021, Particle & Particle Systems Characterization.

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma

G. Requirand, B. Klein, J. Moreaux, 2018, Cytometry. Part B, Clinical cytometry.

Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate-containing silica/collagen xerogels.

D. Hose, R. Schnettler, A. Seckinger, 2018, Journal of biomedical materials research. Part B, Applied biomaterials.

RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine.

V. Beneš, D. Hose, A. Seckinger, 2018, Methods in molecular biology.

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells

J. Moreaux, D. Hose, R. King, 2015, Oncotarget.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

B. Klein, D. Hose, H. Goldschmidt, 2014, Oncotarget.

The Glycome of Normal and Malignant Plasma Cells

B. Klein, J. Moreaux, D. Hose, 2013, PloS one.

Clinical and prognostic role of annexin A2 in multiple myeloma.

T. Rème, B. Klein, J. Moreaux, 2012, Blood.

Clinical and prognostic role of annexin A 2 in multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2012 .

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

J. D. Vos, V. Pantesco, B. Klein, 2009, Oncogene.

Molecular Classification of Multiple Myeloma (MM) Based on Gene Expression Profiling (GEP) and Fluorescence In Situ Hybridisation (FISH) Is an Independent Predictor for Event Free Survival (EFS).

J. D. Vos, T. Rème, J. Rossi, 2005 .

A New Molecular Classification of Multiple Myeloma Using Gene Expression Profiling and Fluorescence In Situ Hybridisation as Predictor for Event Free Survival.

T. Rème, J. Rossi, B. Klein, 2004 .

Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine

Thomas Hielscher, Hartmut Goldschmidt, Dirk Hose, 2011, Clinical Cancer Research.

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study

D. Hose, H. Goldschmidt, A. Jauch, 2016, European Radiology.

Copresentation of BMP-6 and RGD Ligands Enhances Cell Adhesion and BMP-Mediated Signaling

D. Hose, S. Vukicevic, E. A. Cavalcanti-Adam, 2019, Cells.

Cytokine Pathways in Myeloma Growth and Survival

T. Rème, M. Jourdan, J. Rossi, 2009 .

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.

D. Hose, H. Goldschmidt, A. Ho, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

prognostic relevance of the expression of its receptor The role of IGF-1 as a major growth factor for myeloma cell lines and the

T. Rème, M. Jourdan, J. Rossi, 2009 .

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

P. Raynaud, V. Pantesco, T. Rème, 2006, Blood.

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2010 .

FOXM1 is a therapeutic target for high-risk multiple myeloma

D. Hose, H. Goldschmidt, F. Zhan, 2016, Leukemia.

Systematic literature review of health economic models developed for multiple myeloma to support future analyses.

D. Hose, P. Keown, J. Harousseau, 2022, Journal of medical economics.

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry.

D. Hose, W. Haefeli, A. Seckinger, 2014, Journal of chromatography. A.

Visfatin alters the cytokine and matrix-degrading enzyme profile during osteogenic and adipogenic MSC differentiation.

D. Hose, U. Müller-Ladner, S. Rehart, 2018, Osteoarthritis and cartilage.

Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI.

D. Hose, H. Goldschmidt, T. Hielscher, 2012 .

Myeloma of T Cells from Patients with Multiple Activity and Decreases CD45RA Expression Lenalidomide Enhances Antigen-Specific

B. Klein, D. Hose, H. Goldschmidt, 2011 .

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

E. Wagner, D. Hose, H. Goldschmidt, 2021, Leukemia.

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.

D. Hose, H. Goldschmidt, A. Jauch, 2008, Blood.

Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.

D. Hose, H. Ludwig, T. Meissner, 2014, Experimental hematology.

GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells

Thierry Fest, Thierry Rème, Dirk Hose, 2015, PLoS Comput. Biol..

Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells

T. Rème, J. Rossi, B. Klein, 2009, British journal of haematology.

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

G. Requirand, M. Jourdan, J. Moreaux, 2022, Frontiers in Immunology.

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2017, Leukemia.

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

E. Wagner, D. Hose, H. Goldschmidt, 2017, Leukemia.

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis

D. Hose, H. Goldschmidt, A. Jauch, 2017, Haematologica.

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics

D. Hose, H. Goldschmidt, A. Jauch, 2005, Genes, chromosomes & cancer.

A Niche-Dependent Myeloid Transcriptome Signature Defines Dormant Myeloma Cells.

I. Amit, K. Vandyke, D. Hose, 2019, Blood.

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma

T. Rème, J. Rossi, B. Klein, 2012, PloS one.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

D. Hose, H. Goldschmidt, A. Jauch, 2017, Haematologica.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Kinome expression profiling to target new therapeutic avenues in multiple myeloma

M. Jourdan, J. Moreaux, D. Hose, 2019, Haematologica.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients wi

D. Hose, H. Goldschmidt, A. Jauch, 2016, BMC Cancer.

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

P. Sonneveld, M. Kersten, G. Mulligan, 2010, Blood.

Embryonic stem cell markers expression in cancers.

B. Klein, J. Moreaux, D. Hose, 2009, Biochemical and biophysical research communications.

Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma1

Hartmut Goldschmidt, Dirk Hose, Bernard Klein, 2009, The Journal of Immunology.

Cancer-Testis Antigens in Multiple Myeloma PCR Analyses Identify Novel Potential Gene Expression Profiling and Real-Time

G. Requirand, T. Rème, B. Klein, 2009 .

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

V. Pantesco, T. Rème, B. Klein, 2012, Haematologica.

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

D. Hose, H. Goldschmidt, A. Jauch, 2010, Haematologica.

Microarray‐based understanding of normal and malignant plasma cells

K. Tarte, T. Rème, M. Jourdan, 2006, Immunological reviews.

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2014, Oncotarget.

Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation

K. Tarte, T. Rème, M. Jourdan, 2011, The Journal of Immunology.

An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization.

M. Jourdan, B. Klein, D. Hose, 2009, Blood.

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

V. Pantesco, T. Rème, J. Rossi, 2005, Blood.

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma

J. D. Vos, G. Requirand, T. Rème, 2006, Oncogene.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

G. Requirand, J. Moreaux, D. Hose, 2018, Clinical Epigenetics.

Pacemaker cell characteristics of differentiated and HCN4-transduced human mesenchymal stem cells.

A. Draguhn, C. Bruehl, D. Hose, 2019, Life Science.

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

M. Kersten, D. Hose, H. Goldschmidt, 2018, Leukemia.

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

M. Kersten, D. Hose, H. Goldschmidt, 2015 .

Gene expression of anti‐ and pro‐apoptotic proteins in malignant and normal plasma cells

V. Pantesco, T. Rème, M. Jourdan, 2009, British journal of haematology.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2015, Haematologica.

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Cancers.

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Leukemia.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood Cancer Journal.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood cancer journal.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2018, Leukemia.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2015, Leukemia.

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

D. Hose, H. Goldschmidt, A. Jauch, 2013 .

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

D. Hose, H. Goldschmidt, A. Jauch, 2012, Blood.

The Value of Anti-angiogenics in Multiple Myeloma Therapy

D. Hose, H. Goldschmidt, A. Seckinger, 2019, Tumor Angiogenesis.

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.

Thomas W. Mühleisen, T. Mühleisen, M. Nöthen, 2014, Blood.

The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

Asta Försti, Lewin Eisele, Hartmut Goldschmidt, 2013, Nature Genetics.

DNA repair pathways in human multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2013, Cell cycle.

Sorafenib in patients with refractory or recurrent multiple myeloma

D. Hose, H. Goldschmidt, I. Schmidt-Wolf, 2013, Hematological oncology.

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

D. Hose, H. Goldschmidt, A. Jauch, 2017, Haematologica.

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Marina Ruggeri, Dirk Hose, Alberto Orfao, 2008, Haematologica.

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis

G. Lenz, D. Hose, H. Goldschmidt, 2021, Frontiers in Oncology.

DNA methylation score is predictive of myeloma cell sensitivity to 5‐azacitidine

B. Klein, J. Moreaux, D. Hose, 2014, British journal of haematology.

T cell‐based targeted immunotherapies for patients with multiple myeloma

D. Hose, H. Goldschmidt, A. Ho, 2015, International journal of cancer.

TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

T. Rème, M. Jourdan, B. Klein, 2007, Haematologica.

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

D. Hose, B. Barlogie, N. Munshi, 2018, JCI insight.

Thymosin β4 in multiple myeloma: friend or foe

B. Klein, D. Hose, K. Vanderkerken, 2010, Annals of the New York Academy of Sciences.

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

G. Requirand, T. Rème, B. Klein, 2013, British Journal of Cancer.

Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma

B. Klein, D. Hose, H. Goldschmidt, 2011, The Journal of Immunology.

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

D. Hose, H. Goldschmidt, A. Jauch, 2017 .

Beyond medicines’ barriers: exploring the true cost of multiple myeloma

D. Hose, P. Keown, J. Harousseau, 2022, Journal of medical economics.

Modeling risk stratification in human cancer

Thierry Rème, Dirk Hose, Charles Theillet, 2013, Bioinform..

Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis1

P. Raynaud, V. Pantesco, T. Rème, 2007, The Journal of Immunology.

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells

T. Rème, B. Klein, J. Moreaux, 2013, PloS one.

Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation

M. Jourdan, B. Klein, D. Hose, 2010, Leukemia.

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Bart Barlogie, Hartmut Goldschmidt, Dirk Hose, 2009, Blood.

A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments

Hartmut Goldschmidt, Thierry Rème, Dirk Hose, 2008, BMC Bioinformatics.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

D. Hose, T. Phan, J. Pettitt, 2017, Blood.

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

T. Rème, M. Jourdan, J. Rossi, 2010, BMC Cancer.

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics

D. Hose, H. Goldschmidt, O. Stegle, 2021, Nature Communications.

18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma: Patterns of Tracer Uptake and Correlation With Bone Marrow Plasma Cell Infiltration Rate

D. Hose, H. Goldschmidt, A. Dimitrakopoulou-Strauss, 2015, Clinical nuclear medicine.

Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.

D. Hose, M. Peppelenbosch, D. Chesik, 2010, Experimental cell research.

Identification of HLA‐A2 restricted T‐cell epitopes within the conserved region of the immunoglobulin G heavy‐chain in patients with multiple myeloma

B. Klein, D. Hose, H. Goldschmidt, 2008, European journal of haematology.

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

B. Klein, D. Hose, H. Goldschmidt, 2006, Experimental hematology.

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria.

D. Hose, H. Goldschmidt, A. Jauch, 2020, Blood.

molecule-6 cells through carcinoembryonic antigen-related cell adhesion Tumor cells in multiple myeloma patients inhibit myeloma-reactive

T. Rème, J. Rossi, B. Klein, 2013 .

Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24

B. Klein, D. Hose, H. Goldschmidt, 2009, Journal of immunotherapy.

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

Christine L. P. Eng, Sandeep Kumar Dhanda, H. Dai, 2019, bioRxiv.

Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

T. Rème, B. Klein, D. Hose, 2011, Experimental hematology.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

D. Hose, H. Goldschmidt, A. Jauch, 2016, Blood.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, BMC Cancer.

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

D. Hose, H. Goldschmidt, A. Jauch, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.

B. Klein, D. Hose, A. Seckinger, 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2016, British Journal of Cancer.

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

D. Hose, H. Goldschmidt, A. Jauch, 2011, Blood.

Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications

T. Rème, M. Jourdan, J. Rossi, 2007, Clinical Cancer Research.

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2022, Blood Cancer Journal.

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Hyaluronan Hydrogels delivering BMP-6 for local targeting of malignant plasma cells and osteogenic differentiation of mesenchymal stromal cells.

D. Hose, E. A. Cavalcanti-Adam, A. Seckinger, 2019, Acta biomaterialia.

Autologous retransplantation for patients with recurrent multiple myeloma

D. Hose, H. Goldschmidt, A. Ho, 2013, Cancer.

Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma

D. Hose, H. Goldschmidt, S. Delorme, 2012, Haematologica.

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

D. Hose, H. Goldschmidt, A. Jauch, 2011, Cancer.

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Axel Benner, Thomas Hielscher, Bart Barlogie, 2008, Blood.

High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH.

D. Hose, H. Goldschmidt, A. Jauch, 2005, Cancer genetics and cytogenetics.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma

D. Hose, H. Goldschmidt, A. Ho, 2018, Cytometry. Part B, Clinical cytometry.

Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up

D. Hose, H. Goldschmidt, A. Jauch, 2021, British journal of haematology.

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

T. Rème, B. Klein, J. Moreaux, 2011, Srpski arhiv za celokupno lekarstvo.

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

M. Kersten, D. Hose, H. Goldschmidt, 2013 .

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma

D. Hose, H. Goldschmidt, S. Delorme, 2014, Clinical Cancer Research.

MYEOV is a prognostic factor in multiple myeloma.

T. Rème, B. Klein, J. Moreaux, 2010, Experimental hematology.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion

J. Moreaux, D. Hose, A. Kassambara, 2017, Cancer Immunology Research.

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma

D. Hose, K. Breckpot, M. Törngren, 2023, Journal for ImmunoTherapy of Cancer.

Osteocyte Regulation of Receptor Activator of NF-κB Ligand/Osteoprotegerin in a Sheep Model of Osteoporosis.

D. Hose, H. Wilke, A. Ignatius, 2017, The American journal of pathology.

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2016, Haematologica.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation

H. Kauczor, D. Hose, H. Goldschmidt, 2009, Clinical Cancer Research.

Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage

V. Pantesco, M. Jourdan, B. Klein, 2016, Cell cycle.

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2016, American journal of hematology.

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2017 .

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors

G. Requirand, T. Rème, B. Klein, 2012, Molecular Cancer Therapeutics.

MCT-12-0721 2685..2692

G. Requirand, T. Rème, B. Klein, 2012 .

Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation

D. Hose, H. Goldschmidt, T. Hielscher, 2013, International Journal of Hematology.

IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors

K. Tarte, M. Jourdan, B. Klein, 2014, Leukemia.

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis

D. Hose, B. Ghesquière, K. Vanderkerken, 2022, Journal of experimental & clinical cancer research : CR.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2013, Haematologica.

Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma

D. Hose, F. Prósper, J. Miguel, 2015 .

D. Hose, H. Goldschmidt, A. Jauch, 2019, BMC Cancer.

deletion 17p transplantation improves outcome in multiple myeloma patients with Administration of bortezomib before and after autologous stem cell

D. Hose, H. Goldschmidt, A. Jauch, 2012 .

Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma

H. Kauczor, D. Hose, H. Goldschmidt, 2008, International journal of cancer.

D. Hose, H. Goldschmidt, A. Jauch, 2016, BMC Cancer.

Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma

D. Hose, H. Goldschmidt, A. Ho, 2015, Clinical Cancer Research.

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma

B. Klein, D. Hose, H. Goldschmidt, 2010, Haematologica.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Resemblance-Ranking Peptide Library to Screen for Binders to Antibodies on a Peptidomic Scale

D. Hose, A. Seckinger, R. Popov, 2022, International journal of molecular sciences.

Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters

D. Hose, W. Haefeli, A. Seckinger, 2015, Cancer Chemotherapy and Pharmacology.

A niche

I. Amit, K. Vandyke, D. Hose, 2004 .

NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm

B. Klein, J. Moreaux, D. Hose, 2010, Genes, chromosomes & cancer.

Gene Expression Profiling and Real-Time PCR Analyses Make It Possible To Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma.

J. D. Vos, G. Requirand, T. Rème, 2007 .

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells

B. Klein, J. Moreaux, D. Hose, 2015, Haematologica.

Abstract 4725: Multiple Myeloma DREAM Challenge: A crowd-sourced challenge to improve identification of high-risk patients

Thomas Yu, Fadi Towfic, Justin Guinney, 2017 .

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

D. Hose, H. Goldschmidt, G. Morgan, 2015, BMC Medical Genomics.

Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2014, Leukemia.

A tissue-based approach to selection of reference genes for quantitative real-time PCR in a sheep osteoporosis model

D. Hose, A. Seckinger, A. Rösen‐Wolff, 2017, BMC Genomics.

DNA repair pathways in human multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2013, Cell cycle.

707 A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers

D. Hose, G. Curigliano, A. Seckinger, 2022, Regular and Young Investigator Award Abstracts.

Association of Antigen-specific T-cell Responses with Antigen-expression and Immunoparalysis in Multiple Myeloma Statement of Translational Relevance

D. Hose, M. Hundemer, Brigitte Neuber, 2022 .

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

B. Klein, D. Hose, A. Seckinger, 2012 .

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

J. Moreaux, D. Hose, C. Heirman, 2018, Cancer research.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

M. Kersten, D. Hose, H. Goldschmidt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

T. Rème, J. Rossi, B. Klein, 2011, Haematologica.

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

T. Rème, J. Rossi, B. Klein, 2012 .

Determined by Microarray Analysis Expression Patterns and Prognosis Value Cancer/Testis Genes in Multiple Myeloma:

J. D. Vos, P. Raynaud, V. Pantesco, 2007 .

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

B. Klein, D. Hose, H. Goldschmidt, 2006, Experimental hematology.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

G. Requirand, J. Moreaux, D. Hose, 2018, Clinical Epigenetics.

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

D. Hose, A. Seckinger, L. Shang, 2023, Journal of Hematology & Oncology.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

T. Rème, M. Jourdan, B. Klein, 2011, Haematologica.

Thymosin β4 in multiple myeloma: friend or foe

B. Klein, D. Hose, K. Vanderkerken, 2010, Annals of the New York Academy of Sciences.